Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 03/26/25 | 8-K | Current report |
|
   |
2 |
| 03/19/25 | 8-K | Current report |
|
|
4 |
| 02/26/25 | 8-K | Current report |
|
|
4 |
| 02/21/25 | 3 | Initial statement of beneficial ownership of securities |
|
2 | |
| 02/19/25 | 8-K | Current report filing |
|
|
4 |
| 02/13/25 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
32 |
| 02/13/25 | 8-K | Current report filing |
|
|
5 |
| 01/31/25 | EFFECT | Notice of Effectiveness |
|
1 | |
| 01/31/25 | EFFECT | Notice of Effectiveness |
|
1 | |
| 01/31/25 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
14 |
